Gene expression analysis of troglitazone reveals its impact on multiple pathways in cell culture: A case for in vitro platforms combined with gene expression analysis for early (idiosyncratic) toxicity screening

International Journal of Toxicology

Volumn 25, Issue 2, 2006, Pages 85-94

  Vansant, Gordon ^a   Pezzoli, Patrick ^a   Saiz, Robert ^a   Birch, Aaron ^a   Duffy, Chris ^a   Ferre, Francois ^a   Monforte, Joseph ^a  

^a Althea Technologies   (United States)

Author keywords

Gene Expression Analysis; Glitazones; Idiosyncratic Toxicity; Multiplex PCR

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL LINE; CELL PROLIFERATION; CLONE; CONTROLLED STUDY; DNA DAMAGE; GENE EXPRESSION; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIVER CELL; LIVER TOXICITY; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; SCREENING; STATISTICAL SIGNIFICANCE; XENOBIOTIC METABOLISM;

ANIMALS; CELL LINE; CELLS, CULTURED; CHROMANS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEPATOCYTES; HYPOGLYCEMIC AGENTS; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIAZOLIDINEDIONES;

ANIMALIA;

EID: 33645757567     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1080/10915810600605690     Document Type: Article

References (46)

1. Bae, M. A., H. Rhee, and B. J. Song. 2003. Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines. Toxicol. Lett. 139:67-75.
2. Balla, J., G. M. Vercellotti, K. Nath, A. Yachie, E. Nagy, J. W. Eaton, and G. Balla. 2003. Haem, haem oxygenase and ferritin in vascular endothelial cell injury. Nephrol. Dial. Transplant. 18(Suppl. 5):v8-v12.
3. Bell, D. S., and F. Ovalle. 2000. Late-onset troglitazone-induced hepatic dysfunction. Diabetes Care 23:128-129 letter; comment.
4. Barouki, R., and Y. Morel. 2001. Repression of cytochrome P450 1A1 gene expression by oxidative stress: mechanisms and biological implications. Biochem. Pharmacol. 61:511-516.
5. Bondy, S. C., and S. Naderi. 1994. Contribution of hepatic cytochrome P450 systems to the generation of reactive oxygen species. Biochem. Pharmacol. 48:155-159.
6. Corazzari, M., P. E. Lovat, S. Oliverio, A. D. Pearson, M. Piacentini, C. P. Redfern. 2003. Growth and DNA damage-inducible transcription factor 153 mediates apoptosis in response to fenretinide but not synergy between fenretinide and chemotherapeutic drugs in neuroblastoma. Mol. Pharmacol. 64:1370-1378.
7. Cossi, L., E. P. Maineri, N. Traverso, N. Rosatto, M. A. Pronzato, D. Cottalasso, U. M. Marinari, and P. Odetti. 2001. Induction of heme oxygenase 1 in liver of spontaneously diabetic rats. Free Radic. Res. 34:189-191.
8. Davies, G. F., P. J. McFie, R. L. Khandelwal, and R. J. Roesler. 2002. Unique ability of troglitazone to up-regulate peroxisome proliferator-activated receptor-γ expression in hepatocytes. J. Pharmacol. Exp. Ther. 300:72-77.
9. Evans, R. M. 1988. The steroid and thyroid hormone receptor superfamily. Science 240:889-895.
10. Fukano, M., S. Amano, J. Sato, K. Yamamato, H. Adachi, Y. Fujiyama, and T. Bamba. 2000. Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: A case report with autopsy examination. Hum. Pathol. 31:250-253.
11. Ganey, P. E., J. P. Luyendyk, J. F. Maddox, and R. A. Roth. 2004. Adverse hepatic drug reactions: Inflammatory episodes as consequence and contributor. Chem. Biol. Interact. 150:35-51.
12. Gitlin, N., N. L. Julie, C. L. Spurr, K. N. Lim, and H. M. Juarbe. 1998. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann. Intern. Med. 129:36-38.
13. He, K., T. F. Woolf, A. E. Fielder, and R. E. Talaat. 2001. Troglitazone formulation catalyzed by human and rat CYP3A: An atypical CYP oxidation reaction. Biochem. Pharmacol. 62:191-198.
14. Heinemeyer G., S. Nigan, and A. G. Hildebrandt. 1980. Hexobarbital-binding, hydroxylation and hexobarbital-dependent hydrogen peroxide production in hepatic microsomes of guinea pig, rat and rabbit. Naunyn-Schmiedeberg's Arch. Pharmacol. 314:201-210.
15. Herrine, S. K., and C. Choudary. 1999. Severe hepatotoxicity associated with troglitazone. Ann. Intern. Med. 130:163-164.
16. Honma, W., M. Shimada, H. Sasano, O. Shogo, M. Miyata, K. Nagata, T. Ikeda, and Y. Yamazoe. 2002. Phenol sulfotransferase, ST1A3, as the major enzyme catalyzing sulfation of troglitazone in human liver. Drug Metab. Dispos. 30:944-949.
17. Horvath, I., L. E. Donnelly, A. Kiss, P. Paredi, S. A. Kharitonov, and P. J. Barnes. 1998. Raised levels of exhaled carbon dioxide are associated with an increased expression of heme oxygenase-1 in airway macrophages in asthma: A new marker of oxidative stress. Thorax 53:668-672.
18. Imaoka, S., M. Osada, Y. Minamiyama, T. Yukimura, S. Toyokuni, S. Takemura, T. Hiroi, and Y. Funae. 2004. Role of Phenobarbital inducible cytochrome P450s as a source of active oxygen species in DNA oxidation. Cancer Lett. 203:117-125.
19. Kamalvand, G., G. Pinard, and Z. Ali-Khan. 2003. Heme-oxygenase-1 response, a marker of oxidative stress, in a mouse model of AA amyloidosis. Amyloid 10:151-159.
20. Li, J., T. Kaneko, Y. Wang, Q. Li-Quang, P.Y. Wang, and A. Sato. 2002. Troglitazone enhances the hepatotoxicity of acetaminophen by inducing CYP3A in rats. Toxicology 176:91-100.
21. Li, P. L. 2002. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity. Chem. Biol. Interact. 142:7-23.
22. Loi, C. M., E. J. Randinitis, A. B. Vassos, D. J. Kazierad, J. R. Koup, and A. J. Sedman. 1997. Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple dose study. J. Clin. Pharmacol. 37:1114-1120.
23. 2enhances allyl alcohol-induced toxicity in rat hepatocytes. Toxicol. Sci. 77:290-298.
24. Misbin, R. I. 1999. Troglitazone-associated hepatic failure. Ann. Intern. Med. 130:330 letter; comment.
25. Murphy, E. J., T. J. Davern, A. O. Shakil, L. Shick, U. Masharani, H. Chow, C. Feise, W. M. Lee, and N. M. Bass. 2000. Troglitazone-induced fulminant hepatic failure. Dig. Dis. Sci. 45:549-553.
26. Neushwander-Tetri, B. A., W. L. Isley, J. C. Oki, S. Ramrakhiani, S. G. Quison, N. J. Phillips, and E. M. Brunt. 1998. Troglitazone-induced hepatic failure leading to liver transplantation. Ann. Intern. Med. 129:38-41.
27. Paolini, M., A. Alessandra, L. Pozzetti, D. Spetlova, P. Perocco, L. Valgimigli, G. F. Pedulli, and G. Cantelli-Forti. 2001. Induction of cytochrome P450 enzymes and over-generation of oxygen radicals in beta-carotene supplemented rats. Carcinogenesis. 22 (9):1483-1495.
28. Park, B. K., M. Pirmohamed, and N. R. Kitteringham. 1998. Role of drag disposition in drug hypersensitivity: A clinical, molecular, and clinical perspective. Chem. Res. Toxicol. 11:969-988.
29. Prabhu, S., A. Fackett, S. Lloyd, H. A. McClellan, C. M. Terrell, P. M. Silber, and A. P. Li. 2002. Identification of glutathione conjugates of troglitazone in human hepatocytes. Chem. Biol. Interact. 142:83-97.
30. Puntarulo, S., and A. I. Cederbaum. 1998. Production of reactive oxygen species by microsomes enriched in specific human cytochrome P450 enzymes. Free Radic. Biol. Med. 24:1324-1330.
31. Ryter, S. W., and R. M. Tyrrell. 2000. The heme synthesis and degradation pathways: Role in oxidant sensitivity. Heme oxygenase has both pro- and antioxidant properties. Free Radic. Biol. Med. 28:289-309.
32. Sahi, J., G. Hamilton, M. Sinz, S. Barros, S. M. Huang, L. J. Lesko, and E. L. LeCluyse. 2000. Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes. Xenobiotica 30:273-284.
33. Saltiel, A. R., and J. M. Olefsky. 1996. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669.
34. Satoh, T., M. Toyoda, H. Hoshino, T. Monden, M. Yamada, H. Shimizu, K. Miyamoto, and M. Mori. 2002. Activation of peroxisome proliferators-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible gene in non-small cell lung carcinoma cells. Oncogene 21:2171-2180.
35. Seguin, B., and J. Uetrecht. 2003. The danger hypothesis applied to idiosyncratic drug reactions. Curr. Opin. Allergy Clin. Immunol. 4:235-242.
36. Shibata, H., S. Nii, M. Kobayashi, T. Izumi, E. Maeda, K. Sasahara, A. Morita, and A. Nishiwaki. 1993. Phase I study of a new hypoglycemic agent CS-045 in healthy volunteers - safety and pharmacokinetics in single administration. Rinsho Iyuku 9:1503-1518.
37. Spiegelman, B. M. 1998. PPAR-gamma: Adipogenic regulator and thiozolidinedione receptor. Diabetes 47:507-514.
38. Stokes, A. H., W. M. Freeman, S. G. Mitchell, T. A. Burnette, G. M. Hellmann, and K. M. Vrana. 2002. Induction of GADD45 and GADD153 in neuroblastoma cells dopamine-induced toxicity. Neurotoxicity 23:675-684.
39. Summary Basis for Approvals [SBA]. 1997. Summary Basis for Approvals, No. 9, troglitazone, The Society of Japanese Pharmacopoeia, Tokyo.
40. Takekawa, M., and H. Saito. 1998. A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK. Cell 95:521-530.
41. Tyrell, R. M., and S. Basu-Modak. 1994. Transient enhancement of heme oxygenase 1 mRNA accumulation: A marker of oxidative stress to eukaryotic cells. Methods Enzymol. 234:224-235.
42. Vella, A., P. C. de Groen, and S. F. Dinneen. 1998. Fatal hepatotoxicity associated with Troglitazone. Ann. Intern. Med. 129:1080.
43. Watkins, P. B., and R. W. Whitcomb. 1998. Hepatic dysfunction associated with troglitazone. N. Engl. J. Med. 338:916-917.
44. Willson, T. M., P. J. Brown, D. D. Sternbach, and B. R. Henke. 2000. The PPARs: From orphan receptors to drug discovery. J. Med. Chem. 43:527-550.
45. Yamamoto, Y., H. Yamazaki, T. Ikeda, T. Watanabe, H. Iwabuchi, M. Nakajima, and T. Yokoi. 2002. Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxic to HepG2 cells. Drug Metab. Dispos. 30:155-160.
46. Yin, F., D. Bruemmer, F. Blaschke, W. A. Hsueh, R. E. Law, and A. J. Van Herle. 2004. Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells. Oncogene 23:4614-4623.